PMID- 37512070
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230801
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 59
IP  - 7
DP  - 2023 Jul 6
TI  - Antimicrobial and Defense Proteins in Chronic Rhinosinusitis with Nasal Polyps.
LID - 10.3390/medicina59071259 [doi]
LID - 1259
AB  - Background and Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) 
      presently remains a difficult disease to manage. Antimicrobial and defense 
      proteins are important factors that could help characterize the role of 
      microorganisms in CRSwNP pathogenesis, as the concept of microbial dysbiosis in 
      CRS is still being considered. Our aim is to investigate the complex appearance, 
      relative distribution and interlinks of human beta defensin 2 (HBD-2), human beta 
      defensin 3 (HBD-3), human beta defensin 4 (HBD-4), and cathelicidin LL 37 (LL 37) in 
      chronic rhinosinusitis with nasal polyps (CRSwNP)-affected human nasal mucosa. 
      Materials and Methods: The study group consisted of 48 samples from patients with 
      CRSwNP. Samples were collected during functional endoscopic sinus surgery. The 
      control group consisted of 17 normal healthy nasal mucosa samples gathered during 
      routine septoplasty. beta-defensin-2, beta-defensin-3, beta-defensin-4 and cathelicidin LL 
      37 in tissue were detected via immunohistochemical analysis. Results: HBD-2, 
      HBD-3 and LL 37 were significantly decreased in epithelial cells in both primary 
      and recurrent nasal polyp samples (p < 0.001) in comparison to control samples. 
      HBD-2 was decreased in the subepithelial connective tissue of primary nasal polyp 
      samples when compared to both recurrent polyp (p = 0.050) and control (p = 0.033) 
      samples. In subepithelial connective tissue, significantly more HBD-3-positive 
      structures were observed in primary nasal polyp samples (p = 0.049) than in 
      control samples. In primary polyp samples, moderate correlations between 
      connective tissue HBD-3 and connective (R = 0.584, p = 0.001) and epithelial 
      tissue LL 37 (R = 0.556, p = 0.002) were observed. Conclusions: Decreased HBD-2, 
      HBD-3 and LL 37 concentrations in the epithelium suggest a dysfunction of the 
      epithelial barrier in patients with nasal polyps. Decreased subepithelial 
      connective tissue HBD-2 suggests different responses to nasal microbiota in 
      patients with primary nasal polyps compared to recurrent nasal polyps. Increased 
      HBD-3 in subepithelial connective tissue suggests a possible role of this 
      antimicrobial peptide in the pathogenesis of primary nasal polyps.
FAU - Viksne, Rudolfs Janis
AU  - Viksne RJ
AUID- ORCID: 0000-0003-2052-8294
AD  - Department of Otorhinolaryngology, Riga Stradins University, Pilsonu Street 13, 
      LV-1002 Riga, Latvia.
AD  - Daugavpils Regional Hospital, Vasarnicu Street 20, LV-5417 Daugavpils, Latvia.
FAU - Sumeraga, Gunta
AU  - Sumeraga G
AD  - Department of Otorhinolaryngology, Riga Stradins University, Pilsonu Street 13, 
      LV-1002 Riga, Latvia.
AD  - Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, 
      Latvia.
FAU - Pilmane, Mara
AU  - Pilmane M
AUID- ORCID: 0000-0001-9804-4666
AD  - Institute of Anatomy and Anthropology, Riga Stradins University, Kronvalda 
      Boulevard 9, LV-1010 Riga, Latvia.
LA  - eng
PT  - Journal Article
DEP - 20230706
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (beta-Defensins)
RN  - 0 (Cathelicidins)
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Humans
MH  - *beta-Defensins/metabolism
MH  - *Nasal Polyps/complications/metabolism/pathology
MH  - Cathelicidins
MH  - *Sinusitis/complications/pathology
MH  - *Anti-Infective Agents
MH  - Chronic Disease
PMC - PMC10383322
OTO - NOTNLM
OT  - cathelicidins
OT  - defensins
OT  - nasal polyps
OT  - rhinosinusitis
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:52
MHDA- 2023/07/31 06:42
PMCR- 2023/07/06
CRDT- 2023/07/29 01:28
PHST- 2023/06/04 00:00 [received]
PHST- 2023/07/03 00:00 [revised]
PHST- 2023/07/04 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/29 11:52 [pubmed]
PHST- 2023/07/29 01:28 [entrez]
PHST- 2023/07/06 00:00 [pmc-release]
AID - medicina59071259 [pii]
AID - medicina-59-01259 [pii]
AID - 10.3390/medicina59071259 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2023 Jul 6;59(7):1259. doi: 10.3390/medicina59071259.